MRS1334

• CAT Number: M042767
• CAS Number: 192053-05-7
• Molecular Formula: C31H26N2O6
• Molecular Weight: 522.55
• Purity: ≥95%
• Synonyms: 3-O-ethyl 5-O-[(4-nitrophenyl)methyl] 2-methyl-6-phenyl-4-(2-phenylethynyl)-1,4-dihydropyridine-3,5-dicarboxylate
• InChI: InChI=1S/C31H26N2O6/c1-3-38-30(34)27-21(2)32-29(24-12-8-5-9-13-24)28(26(27)19-16-22-10-6-4-7-11-22)31(35)39-20-23-14-17-25(18-15-23)33(36)37/h4-15,17-18,26,32H,3,20H2,1-2H3
• InChIKey: QFLOJAMZLQXHFS-UHFFFAOYSA-N
• SMILES: CCOC(=O)C1=C(NC(=C(C1C#CC2=CC=CC=C2)C(=O)OCC3=CC=C(C=C3)[N+](=O)[O-])C4=CC=CC=C4)C

MRS1334 is a potent and selective human adenosine A3 receptor antagonist with Kis of 2.69 nM, >100 nM, >100 nM for hA3, rA1, rA2A, respectively. MRS1334 blocks the protective effect of Cl-IB-MECA leading to significant bradycardia and elevated ST segment[1][2]. MRS1334 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Reference

[1]. P G Baraldi, et al. New potent and selective human adenosine A(3) receptor antagonists. Trends Pharmacol Sci. 2000 Dec;21(12):456-9.
 [Content Brief]

[2]. Aya Galal, et al.  Selective A3 adenosine receptor agonist protects against doxorubicin-induced cardiotoxicity. Cancer Chemother Pharmacol. 2016 Feb;77(2):309-22.
 [Content Brief]